STRATEC SE

Investor Presentation • May 4, 2017

Q1 2017 Financial Results

as of March 31, 2017

Conference Call May 4, 2017

Forward-looking statements involve risks.

This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forwardlooking statements are realistic, we can provide no guarantee of this.

This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected.

It is not planned to update these forward-looking statements.

• 1. Overview of the first three months of 2017
• 1. Financials
• 1. Outlook & Focus in 2017
• 1. Q&A

HIGHLIGHTS Q1 2017

• Sales growth organically and with major clients in instrumentation
• Sales total: +58.6%
• Sales organically: +21.1%
• Financial guidance confirmed
• Highly promising contract negotiations including cross business unit opportunities
• Number of employees > 1,000

• Dividend proposal at € 0.77 per share (previous year: € 0.75)

• Overview of the first three months of 2017

2. Financials

• 1. Outlook & Focus in 2017
• 1. Q&A

FINANCIALS AT A GLANCE

Key figures after the first three months

(in € million)	Mar 31, 2017	Mar 31, 2016	Change
Sales	49.510	31.218	+58.6%
EBITDA1	8.812	5.703	+54.5%
EBITDA margin (%)1	17.8	18.3	-50 bps
EBIT2	6.870	4.530	+51.7%
EBIT margin (%)2	13.9	14.5	-60 bps
Cons. net income2	5.369	3.424	+56.8
2 Earnings per share (€)	0.45	0.29	+55.2

¹ 2017 figure adjusted to exclude expenses resulting from transaction activities and related reorganization expenses

² 2017 figure additionally adjusted to exclude purchase price allocation-related amortization, financing expenses and

tax expenses in connection with the acquisitions of the Diatron Group and STRATEC Consumables

SALES

3-Months Sales compared to Annual Sales

Q1|2017 Sales

• +58.6% to € 49.5 million
• Organic growth +21.1%
• Contribution of Diatron and STRATEC Consumables
• High volume of development activities

Quarterly Statement Q1|2017 Conference Call – May 4, 2017

3-Months Sales as of 03/31

EBIT & EBIT MARGIN

As of March 31

EBIT margin affected by

• Product mix
• Diluted margins from new subsidiaries
• Hiring of staff in connection with numerous product developments

	Overview		Q1 2017		Financials			Outlook & Focus in 2017	Q&A

ADJUSTMENTS

in $\epsilon$ thousand	01.01. - 31.03.2017
EBITDA	8.461
Adjustments
Expenses due to company acquisitions	270
Reorganization expenses	80
Adjusted EBITDA	8.812
Depreciation and Amortization	$-3.778$
Adjustments
PPA Depreciation and Amortization	1.836
Adjusted EBIT	6.870
Net financial expenses	$-275$
Current tax expenses	$-1.252$
Deferred tax income	264
Adjustierungen
Financing expenses due to company acquisitions	220
Current tax expenses	$-157$
Deferred tax expenses	$-301$
Adjusted consilidated net income	5.369

EARNINGS AFTER THREE MONTHS

• Q1 tax rate at 22.4% (previous year: 22.5%)

• Dividend proposal per share at € 0.77 (previous year : € 0.75)

• 1. Overview of the first three months of 2017
• 1. Financials
• 1. Outlook & Focus in 2017
• 1. Q&A

FINANCIAL GUIDANCE

• Sales guidance for 2017: € 205 million to € 220 million
• Organic double digit top line growth in 2017
• Profitability in 2017 on a broadly stable level
• Guidance to be updated with H1 results in July 2017

FOCUS IN 2017 AND BEYOND

• Improve profitability across business (benefits of scale driven by top-line growth)
• Further realize synergies through development activities across STRATEC businesses
• Expand leading market role
• Facilitate process of instrument/consumables integration for partners
• Achieve milestones & market launches
• Execute important development and supply agreements

Quarterly Statement Q1|2017 Conference Call – May 4, 2017

• 1. Overview of the first three months of 2017
• 1. Financials
• 1. Outlook & Focus in 2017
• 1. Q&A

QUESTIONS & ANSWERS

STRATEC Biomedical AG Gewerbestr. 37 75217 Birkenfeld Germany Tel: +49 7082 7916-0 Fax: +49 7082 7916-999 www.stratec.com

Marcus Wolfinger Chairman, Board of Management m.wolfinger@stratec.com

TICKER
Symbol:	SBS.DE
Bloomberg:	SBS:GR
Reuters:	SBSG.DE
ISIN:	DE000STRA555
WKN:	STRA55

THANK YOU FOR YOUR ATTENTION!